Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 6 Colorectal Neoplasms 3 Osteosarcoma 2 Neoplasms 2 Wilms Tumor 1 Small Bowel Adenocarcinoma 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Rectal Neoplasms 1 Rectal Cancer Patients 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive, Peripheral 1 Neuroblastoma 1 Neoplasm Metastasis 1 Metastatic Gastric Adenocarcinoma 1 Metastatic Adenocarcinoma of the Pancreas 1 Hepatoblastoma 1 Fallopian Tube Neoplasms 1 Esophageal Neoplasms 1 Central Nervous System Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Advanced Rectal Cancer 1

Interventions

Fluorouracil 13 pembrolizumab 12 Paclitaxel 12 Oxaliplatin 12 Leucovorin 9 Carboplatin 9 Capecitabine 8 Trastuzumab 7 Nivolumab 7 Cisplatin 7 Radiotherapy 6 Radiation 6 Taxes 5 Esophagectomy 5 Drug Therapy 5 Surgical Procedures, Operative 4 Specimen Handling 4 Irinotecan 4 trastuzumab deruxtecan 3 tislelizumab 3 patritumab deruxtecan 3 Radiotherapy, Intensity-Modulated 3 Proton Therapy 3 Immunotherapy 3 zanidatamab 2 ulixertinib 2 trastuzumab biosimilar HLX02 2 relatlimab 2 durvalumab 2 atezolizumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Esophageal Neoplasms × irinotecan sucrosofate × 90 days × Clear all

NCT03764553 2026-04-07

LyRICX

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Phase 2 Active not recruiting

Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡